CAH vs PFE: fair value comparison
Cardinal Health, Inc. and Pfizer Inc. · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CAH currently sits closer to the top of our discount ranking.
| CAH | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $247.18 | $28.45 |
| 12-month range | $190.22–$239.35 | $24.23–$28.55 |
| Sector rank | #97 of 113 Healthcare | #101 of 113 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CAH fair value analysis · PFE fair value analysis